Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. Dabigatran etexilate was approved by the FDA in 2010. Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran].
Dabigatran Etexilate
| API Name | Alogliptin benzoate |
|---|---|
| CAS No | 211915-06-9 |
| Molecular Formula | C34H41N7O5 |
| Molecular Weight | 627.7 g/mol |
| Synonyms | ethyl 3-[[2-[[4-(N-hexoxycarbonylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate |
Zoho Contact Form
"*" indicates required fields